Cell Therapy
What is Chondron™?
Cartilage Cell Implantation
Chondron™ is a complete regeneration solution to restore patient's own cartilage for Autologous Chondrocyte Transplantation (ACT).
Autologous Chondrocyte Transplantation [ACT] is a novel surgical approach used to treat full-thickness cartilage defects for patients who have significant, symptomatic defects or damage to the cartilage of the knee caused by acute or repetitive trauma.
Small grafts of normal cartilage removed from the patient's damaged joint are treated in a laboratory to obtain cartilage cells. These cells are cultured to expand the cell populations and reimplanted a few weeks later into areas where cartilage is denuded by disease.
There are no reliable estimates of the prevalence of cartilage defects in the knee. Lesions are most likely to arise in sportsmen and women as a result of injury. Up to 20% of individuals sustaining a haemarthosis following a knee injury may have cartilage damage.
Autologous Chondrocyte Transplantation [ACT] is a novel surgical approach used to treat full-thickness cartilage defects for patients who have significant, symptomatic defects or damage to the cartilage of the knee caused by acute or repetitive trauma.
Small grafts of normal cartilage removed from the patient's damaged joint are treated in a laboratory to obtain cartilage cells. These cells are cultured to expand the cell populations and reimplanted a few weeks later into areas where cartilage is denuded by disease.
There are no reliable estimates of the prevalence of cartilage defects in the knee. Lesions are most likely to arise in sportsmen and women as a result of injury. Up to 20% of individuals sustaining a haemarthosis following a knee injury may have cartilage damage.
About the Procedure
Our Fourth generation Chondron™ uses a cell - gel mixture (includes collagen, hyaluronic acid and fibrin) that has fast gelling properties (1 - 5 min) upon transplantation.
The defect status for a patient's cartilage is verified through arthroscopy and if the defect is decided to be recovered with Chondron™ implantation, a small biopsy is implemented from the patient's healthy femoral articular cartilage in less weight bearing area. There is no reported pain or contraindication due to the biopsy of cartilage and applied for a cartilage defect treatment through multi-culture process.
Once the normal cartilage is harvested, it is transported through logistics to RMS Regrow® Lab (near Pune) where a specialized facility for culture process is developed. The culture period takes about four weeks and it is sent back to local surgeon for Chondron™ implantation.
This cell and gel mixture enable even cell distribution three-dimensionally, moldable to fit irregular defect shape and applicable to a larger defect. Thus there is minimal surgical exposure and reduced surgery time.
There is no reported pain or contraindication due to the biopsy of cartilage and applied for a cartilage defect treatment through multi-culture process.
Each single vial of Chondron™ contains approximately 12 million cultured autologous chondrocytes in 0.4 ml of a culture solution and the cell viability is evaluated to be over 80%.
Multicentre experience of ACI - CHONDRON
The defect status for a patient's cartilage is verified through arthroscopy and if the defect is decided to be recovered with Chondron™ implantation, a small biopsy is implemented from the patient's healthy femoral articular cartilage in less weight bearing area. There is no reported pain or contraindication due to the biopsy of cartilage and applied for a cartilage defect treatment through multi-culture process.
Once the normal cartilage is harvested, it is transported through logistics to RMS Regrow® Lab (near Pune) where a specialized facility for culture process is developed. The culture period takes about four weeks and it is sent back to local surgeon for Chondron™ implantation.
This cell and gel mixture enable even cell distribution three-dimensionally, moldable to fit irregular defect shape and applicable to a larger defect. Thus there is minimal surgical exposure and reduced surgery time.
There is no reported pain or contraindication due to the biopsy of cartilage and applied for a cartilage defect treatment through multi-culture process.
Each single vial of Chondron™ contains approximately 12 million cultured autologous chondrocytes in 0.4 ml of a culture solution and the cell viability is evaluated to be over 80%.
Multicentre experience of ACI - CHONDRON
